Recent developments highlight IN8BIO’s clinical progress, financial activities, and strategic initiatives amid restructuring.

• IN8BIO reported promising Phase 1 trial results for INB-200, demonstrating 16.1 months median progression-free survival in glioblastoma patients [N5].
• The company announced positive Phase 1 data for INB-100 in AML patients, including 100% complete remission in treated patients [N8].
• IN8BIO unveiled its next-generation gamma-delta T-cell engager platform and introduced INB-600, a novel platform targeting cancer with a promising safety profile [N8].
• The company announced a private placement financing in December 2025 to support its operations and pipeline development [N3].
• IN8BIO reported a 77% narrowing of its Q2 loss, indicating progress in financial management [N4].
• The company is advancing cancer therapies amid financial restructuring efforts as of March 2026 [N2].
• IN8BIO actively participates in industry conferences to highlight advances in its gamma-delta T cell therapies [N6].
• Recent analysis suggests the stock may find a bottom soon, reflecting market interest in the company’s developments [N1].

The company’s innovative gamma-delta T cell therapy platforms have shown promising early clinical results, including complete remission in AML patients and extended progression-free survival in glioblastoma patients. Continued clinical progress and expansion of the pipeline could enhance its scientific and commercial value. Successful capital raises, such as the recent private placement financing, provide resources to advance development programs. Strong governance and cybersecurity risk management support operational stability. Participation in industry conferences increases visibility and potential collaboration opportunities.

IN8BIO operates in a high-risk clinical-stage biotech environment with ongoing net losses and reliance on external financing. Clinical trial outcomes remain early-stage and may not translate into regulatory approvals or commercial success. Financial restructuring indicates potential challenges in capital management. The company faces risks related to cybersecurity threats, regulatory compliance, and competitive pressures from other immuno-oncology and cell therapy developers. Failure to advance clinical programs or secure sufficient funding could adversely impact operations and valuation.

IN8BIO’s moat is primarily based on its proprietary gamma-delta T cell therapy platforms, which represent a novel approach in oncology and autoimmune disease treatment. The company’s early clinical trial successes and innovative pipeline products such as INB-600 contribute to its competitive positioning. Its specialized technology and clinical expertise in this niche area create barriers to entry for competitors. Additionally, active participation in scientific conferences and ongoing clinical progress support its reputation and potential for future partnerships or licensing opportunities. However, as a clinical-stage biotech company, the moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: The company’s therapies are in early clinical stages, and there is inherent uncertainty whether these will achieve regulatory approval or demonstrate sufficient efficacy and safety in later trials.
• Financial Risk: IN8BIO reports net losses and depends on external financing, including private placements, to fund operations and clinical development, which may dilute existing shareholders or constrain resources.
• Cybersecurity Risk: The company acknowledges cybersecurity threats and has governance and management processes in place, but breaches could disrupt operations, lead to regulatory actions, or cause reputational harm [S1].
• Regulatory and Legal Risk: The company is subject to regulatory oversight and may face legal proceedings; currently, no material legal proceedings are reported, but future issues could impact business.

• IN8BIO, INC. is a biotechnology company focused on developing innovative gamma-delta T cell therapies for oncology and autoimmune diseases.
• The company has reported promising Phase 1 clinical trial results for its INB-200 product, demonstrating a median progression-free survival of 16.1 months in glioblastoma patients.
• IN8BIO has also reported positive Phase 1 data for INB-100 in acute myeloid leukemia (AML) patients, including 100% complete remission in treated patients.
• The company unveiled a next-generation gamma-delta T-cell engager platform and introduced INB-600, a breakthrough gamma-delta T cell platform targeting cancer with a promising safety profile.
• IN8BIO has participated in industry conferences such as the Immuno-Oncology 360° Conference 2025 to highlight advances in its gamma-delta T cell therapies.
• Financially, as of the quarter ended September 30, 2026, the company reported current assets of $15.19 million and current liabilities of $2.63 million, resulting in a current ratio of 5.78, indicating strong short-term liquidity.
• The net income for the same period was a loss of $4.59 million, with basic and diluted earnings per share of -$0.24.
• The company announced a private placement financing in December 2025, indicating efforts to raise capital.
• IN8BIO's board of directors and audit committee oversee cybersecurity risk management, with detailed processes and experienced management personnel involved in mitigating cybersecurity threats.
• The company is not currently involved in any material legal proceedings that could adversely affect its business.
• Recent news coverage includes reports on narrowing losses, clinical progress, pipeline expansion, and financial restructuring.
• The company’s business model and operations are well documented through SEC filings and extensive news coverage, providing clarity on clinical development and financial status.